Treatment of Rheumatoid Arthritis with Immunosuppressive Drugs: II. Immunological Study

Brocteur, J; Moens, ChR.

doi:10.3109/rhe1.1965.11.issue-1-4.26

Cited by 17 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the demonstration in animals that purine analogues, when administered in large doses, can produce a depression in serum gammaglobulin, the usual smaller therapeutic dose in man has been presumed not to influence gammaglobulin synthesis because serum gammaglobulin concentrations generally remained unchanged (7,11,12). In our studies, more than half of the patients showing a significant reduction in IgG synthesis did not demonstrate any significant change in IgG serum concentration.…”

Section: Discussionmentioning

confidence: 51%

See 1 more Smart Citation

The effect of azathioprine on gammaglobulin synthesis in man

Levy¹,

Barnett²,

MacDonald³

et al. 1972

J. Clin. Invest.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 51%

“…Studies in humans treated with azathioprine have revealed no consistent reduction in serum IgG or IgM levels (7,11,12). Serum immunoglobulin concentration, however, may be an unreliable guide to gammaglobulin synthesis since a decrease in synthesis may be accompanied by a decrease in catabolism and serum concentration may remain unchanged.…”

Section: Introductionmentioning

confidence: 99%

The effect of azathioprine on gammaglobulin synthesis in man

Levy¹,

Barnett²,

MacDonald³

et al. 1972

J. Clin. Invest.

View full text Add to dashboard Cite

“…Historically, the use of thiopurines, mercaptopurine and azathioprine, purine antagonists which inhibit DNA and RNA synthesis (Figure 1), in the treatment of inflammatory bowel disease (IBD) was based upon their efficacy in other autoimmune disorders, including systemic lupus erythematous and rheumatoid arthritis[1]. The efficacy of thiopurines in both Crohn’s disease (CD) and ulcerative colitis (UC) has been documented in prospective, double-blind, placebo-controlled trials, with data supporting their beneficial therapeutic effects in inducing and maintaining disease remission, post-operative maintenance in CD, and chemoprevention of colorectal cancer (CRC)[2-6].…”

Section: Introductionmentioning

confidence: 99%

Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective

Axelrad¹,

Roy²,

Lawlor³

et al. 2016

WJG

View full text Add to dashboard Cite

The use of thiopurines in inflammatory bowel disease (IBD) has been examined in numerous prospective, controlled trials, with a majority demonstrating a clinical benefit. We conducted this review to describe the historical and current evidence in the use of thiopurines in IBD. A systematic search was performed on MEDLINE between 1965 and 2016 to identify studies on thiopurines in IBD. The most robust evidence for thiopurines in IBD includes induction of remission in combination with anti-tumor necrosis factor (anti-TNF) agents, and maintenance of remission and post-operative maintenance in Crohn’s disease. Less evidence exists for thiopurine monotherapy in induction of remission, maintenance of ulcerative colitis, chemoprevention of colorectal cancer, and in preventing immunogenicity to anti-TNF. Evidence was often limited by trial design. Overall, thiopurines have demonstrated efficacy in a broad range of presentations of IBD. With more efficacious novel therapeutic agents, the positioning of thiopurines in the management of IBD will change and future studies will analyze the benefit of thiopurines alone and in conjunction with these new medications.

show abstract

“…This study was begun to answer three questions: (1) Is azathioprine useful in the management of rheumatoid arthritis? (2) If so, does it manifest its usefulness through its ability to effect immunosuppression? (3) Or does it exhibit its effect through some anti-inflammatory property?…”

mentioning

confidence: 99%